Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Type 1 diabetes — guidelines

TL;DR — Major guidelines converge on intensive insulin replacement, CGM, individualized targets, structured education, complication screening, and psychosocial care; disagreement is more often about eligibility, timing, resources, and strength of evidence than physiology. ADA Standards are updated annually, ISPAD provides pediatric domain chapters, and NICE issues UK health-system recommendations. The 2024 early-stage consensus adds confirmatory antibody testing, metabolic monitoring, education, and psychosocial support after screening (Phillip 2024, PMID 38912694). Guideline dates matter: device and disease-modification recommendations can become obsolete within a year.

Guideline families

Body/document Population Distinct contribution Currency caveat
ADA Standards 2026 All ages; US/international use Annual integrated care standards Sections update independently
ISPAD 2024 staging Children/adolescents Screening, stages, β-cell preservation Early-stage implementation evolving
ISPAD 2024 targets Children/adolescents Pediatric glycemic targets Resource stratification needed
ISPAD 2022 DKA/HHS Children/adolescents Acute fluid/insulin/electrolyte care Local protocols govern execution
ISPAD 2022 psychosocial Youth/young adults Integrated mental-health care Workforce availability varies
ISPAD 2022 complications Youth Screening by age/duration/risk Adult transition changes framework
NICE NG17/NG18 UK adults/children NHS pathways and cost-aware recommendations Update cadence differs from ADA

The full catalog, URLs, status, and supersession chains are maintained in the guideline registry.

September 2026 updates

  • The updated ADA/EASD adult consensus expands technology, obesity and cardiovascular-risk coverage. Its September correction fixes a C-peptide unit label, without changing numerical values or conclusions (Holt 2026, PMID 42747450; correction PMID 42814152).
  • International population-screening guidance now supplies an age-based implementation framework (Ziegler 2026, PMID 42720753); see screening.
  • EASD now provides a dedicated adult diabetes-distress guideline with conditional, intervention-specific recommendations (Speight 2026, PMID 42744915).
  • An international position statement addresses technology in non-critically ill hospitalized adults, with selection criteria, staff support and confirmatory glucose testing (Olsen 2026, PMID 42771181).

October 2026 checks

  • ISPAD, EASD, and ADA published a transition consensus covering pre-transfer, transfer, and post-transfer. Consensus was reported for 31 statements, to be adjusted locally. The full text was not open, so the statements are cataloged rather than synthesized (de Beaufort 2026, PMID 42784528). See psychosocial care.
  • NICE TA1176, published 9 July 2026, recommends teplizumab within its marketing authorisation for people aged 8 years and over with stage 2 type 1 diabetes, and only if the company provides it under the commercial arrangement. NICE states that the NHS in England must fund it within 90 days of final publication when it is considered the most suitable option (NICE — "Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes (TA1176)", https://www.nice.org.uk/guidance/ta1176, accessed 2026-10-22). This is an England funding decision. See immunotherapy.
  • Live NICE pages retrieved on 2026-10-22 show that NG17 (last updated 17 August 2022; reviewed 30 January 2026) and NG18 (last updated 11 May 2023; reviewed 18 December 2025) will not have their recommendations updated. Both pages note discontinuation of Levemir (insulin detemir), with an anticipated supply end in December 2026, and say NICE is assessing the effect on the recommendations. Dates and URLs are in the guideline registry.

Areas of strong convergence

Domain Common direction Evidence anchor
Insulin Basal-bolus or pump replacement; avoid interruption DCCT benefit (PMID 8366922)
Monitoring Offer/use CGM where feasible DIAMOND and AID RCTs (PMID 28118453; PMID 31618560)
Targets Individualize HbA1c and CGM goals TIR consensus (PMID 31177185)
Hypoglycemia Assess awareness/risk; prescribe rescue glucagon HAAF review (PMID 31389033)
Education Structured, repeated, developmentally appropriate ISPAD education chapter (PMID 36120721)
Psychosocial Routine assessment tied to care ISPAD 2022 (PMID 36464988)
Complications Risk- and duration-based screening ISPAD 2022 (PMID 36537531)
Exercise Plan insulin, carbohydrate, and monitoring ISPAD exercise (PMID 36537529)
Early stage Confirm, stage, monitor, educate 2024 consensus (PMID 38912694)

Glycemic targets

Targets balance chronic exposure against hypoglycemia and burden. The international CGM consensus proposes >70% time 70–180 mg/dL, <4% below 70, and <1% below 54 for most adults (Battelino 2019, PMID 31177185). Pediatric ISPAD 2024 targets reflect improved technology while retaining individualization (de Bock 2024, PMID 39701064).

Guidelines should not be read as a single-number contest. Pregnancy, impaired awareness, limited life expectancy, cognitive dependence, and access instability change acceptable goals and the resources required to pursue them safely.

Technology recommendations

ADA 2026 technology standards incorporate CGM and AID into routine diabetes care (ADA 2026, PMID 41358889). The evidence base includes a 0.6-point adjusted HbA1c benefit for CGM in injection users and an 11-point TIR gain for closed loop versus sensor-augmented pump (Beck 2017, PMID 28118453; Brown 2019, PMID 31618560).

Recommendation strength can exceed local deliverability. A guideline-compliant prescription without coverage, training, consumables, and backup insulin is not implemented care.

Early-stage disease modification

The staging statement defines stages 1–3 (Insel 2015, PMID 26404926). Monitoring consensus requires confirmation on a second sample, periodic metabolic assessment, DKA education, psychosocial support, and discussion of trial or approved therapy for stage 2 (Phillip 2024, PMID 38912694). ISPAD 2024 places this framework in pediatric care (Haller 2024, PMID 39662065).

Acute safety guidance

ISPAD’s DKA/HHS chapter details pediatric acute management (Glaser 2022, PMID 36250645). SGLT-inhibitor consensus emphasizes ketone monitoring and DKA-risk mitigation because glucose may not be markedly elevated (Danne 2019, PMID 30728224). Adjunct use never substitutes for insulin.

Where guidance differs or leaves gaps

Topic Source of variation
Population screening Evidence, infrastructure, cost-effectiveness
Teplizumab delivery Regulatory approval, age, access, infusion capacity
AID priority Device availability and payer rules
HbA1c/TIR target Age, hypoglycemia, pregnancy, resources
Retinal screening interval Baseline status and health-system recall capacity
Adjunctive drugs Regulatory differences and DKA risk
Adult-onset classification Autoantibody/C-peptide access and ancestry calibration

How to use guidelines

  1. Identify document year, population, and jurisdiction.
  2. Separate recommendation from supporting evidence.
  3. Check whether a newer chapter supersedes the cited version.
  4. Translate “offer” into a pathway with funding, training, monitoring, and backup.
  5. Document justified individualization rather than treating targets as pass/fail.

Guideline scope map

Decision ADA 2026 ISPAD NICE International consensus
Classification Annual all-age chapter Pediatric context Separate adult/youth pathways —
Early-stage disease Classification/prevention Dedicated 2024 chapter No equivalent universal program 2015 staging + 2024 monitoring
HbA1c target Individualized; <7% for many adults ≤6.5% with advanced technology when safe; otherwise ≤7.0% Individualized NHS context —
CGM/AID Dedicated technology chapter 2024 monitoring/targets NHS eligibility and cost context TIR framework
DKA Acute-complication standards Dedicated 2022 chapter Sick-day/emergency pathways SGLT mitigation where used
Psychological care Assessment and integration Dedicated 2022 chapter Referral/structured care —

This is a scope comparison, not word-for-word equivalence. Silence can reflect document remit rather than disagreement.

Quantified targets and context

ISPAD recommends HbA1c ≤6.5% (48 mmol/mol) for children/adolescents with access to CGM and AID when safely achievable and ≤7.0% (53 mmol/mol) in other settings (de Bock 2024, PMID 39701064). The resource qualifier prevents a lower target from becoming a penalty for people denied technology.

The international CGM consensus proposes, for many nonpregnant adults, >70% time 70–180 mg/dL, <4% below 70, and <1% below 54, with separate consideration for older/high-risk and pregnant populations (Battelino 2019, PMID 31177185). TIR complements HbA1c by exposing lows and variability.

Context Why one target fails Adjustment
Severe hypoglycemia/IAH Lower average may be unsafe during restoration Prioritize avoidance
Pregnancy Fetal exposure needs narrower range Use 63–140 mg/dL target
Young children Variable intake and caregiver delivery Technology-supported individualization
Limited resources Unavailable CGM/AID alters achievable risk Do not equate access failure with nonadherence
Frailty/cognitive decline Complexity and rescue capacity Prevent symptomatic extremes with relaxed targets

Pediatric operational chapters

ISPAD separates principles from implementation domains. The 2022 insulin chapter covers preparation, regimen, timing, and adjustment (Cengiz 2022, PMID 36537533); hypoglycemia guidance covers definitions, assessment, treatment, and glucagon (Abraham 2022, PMID 36537534); nutrition guidance integrates carbohydrate estimation, growth, cardiovascular risk, and disordered eating (Annan 2022, PMID 36468223).

Technology guidance evolves quickly. The 2022 glucose-monitoring chapter was followed by a 2024 update covering current CGM and AID integration (Tauschmann 2022, PMID 36537528; Tauschmann 2024, PMID 39884260). A registry should preserve both but mark the older chapter superseded for monitoring technology.

Genuine disagreements and implementation gaps

Topic Position A Position B/context Missing evidence
Universal antibody screening DKA reduction and treatment eligibility favor implementation Some systems await capacity and cost-effectiveness Screening versus optimized awareness
Pediatric HbA1c ISPAD ≤6.5% with technology when safe Other frameworks retain <7% broadly Decades-long lower-target outcomes
AID entitlement Guidance favors broad offering Payer/NICE assessments impose criteria Effect of default coverage on inequity
SGLT adjuncts Consensus defines ketone mitigation Approvals/acceptance vary because DKA persists Net benefit in selected AID-era adults
Teplizumab Stage-2 delay established Repeat dosing and population-screen use unsettled Durable effectiveness
Complication intervals Screening essential Individual interval algorithms differ Modern noninferiority evidence

These differences combine evidence and values: acceptable toxicity in an asymptomatic child, willingness to pay, and tolerance for rare DKA cannot be decided by effect size alone.

Evidence-to-recommendation gaps

Recommendation Evidence anchor Missing bridge
AID for most T1D RCT TIR gains ~10–12 points Population severe events/discontinuation
Earlier screening Low DKA in monitored cohorts Cost, anxiety, retention, infusion capacity
Lower pediatric target Safer exposure reduction with technology Lifetime complications/neurocognition
Psychosocial screening Distress prevalence and association Matched intervention effectiveness
Individual retinal intervals DCCT/EDIC models CGM/AID-era validation
Thyroid/celiac surveillance High prevalence Optimal frequency and cost-effectiveness

Guidelines appropriately recommend under uncertainty, but certainty and value judgments should remain visible. Strong recommendation wording does not imply randomized morbidity or mortality evidence for every component.

Supersession discipline

  • ADA chapters are annual; the 2026 chapters replace older annual general recommendations for the cited topics (PMIDs: 41358889, 41358893, 41358900).
  • ISPAD 2024 early-stage guidance updates the 2022 staging material (Haller 2024, PMID 39662065).
  • ISPAD 2024 glucose-monitoring guidance updates the 2022 technology chapter (Tauschmann 2024, PMID 39884260).
  • The 2015 staging statement remains foundational terminology; 2024 monitoring guidance operationalizes follow-up.
  • NICE NG17/NG18 are live web guidelines; update date and accessed date must be tracked separately. The 2026-10-22 retrieval found surveillance decisions not to update either guideline's recommendations.
  • NICE TA1176 is an England technology appraisal for stage-2 teplizumab funding. It does not replace NG17 or NG18.

Open questions

  • How should the 2026 population-screening consensus be implemented and evaluated across health systems? (Ziegler 2026, PMID 42720753)
  • What real-world monitoring interval prevents DKA with least burden after a positive screen? (Phillip 2024, PMID 38912694)
  • How should guidelines grade evidence when device RCTs use rapidly obsolete comparators? (Di Molfetta 2024, PMID 39298688)
  • Which recommendations worsen inequity when issued without implementation resources? (Foster 2019, PMID 30657336)

References

  1. DCCT Research Group. Effect of intensive treatment on complications. N Engl J Med. 1993;329:977-986. PMID 8366922
  2. Insel RA, et al. Staging presymptomatic T1D. Diabetes Care. 2015;38:1964-1974. PMID 26404926
  3. Battelino T, et al. Clinical Targets for CGM Data Interpretation. Diabetes Care. 2019;42:1593-1603. PMID 31177185
  4. Glaser N, et al. ISPAD 2022: DKA and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2022;23:835-856. PMID 36250645
  5. de Wit M, et al. ISPAD 2022: Psychological care. Pediatr Diabetes. 2022;23:1373-1389. PMID 36464988
  6. Adolfsson P, et al. ISPAD 2022: Exercise. Pediatr Diabetes. 2022;23:1341-1372. PMID 36537529
  7. Bjornstad P, et al. ISPAD 2022: Microvascular and macrovascular complications. Pediatr Diabetes. 2022;23:1432-1450. PMID 36537531
  8. Haller MJ, et al. ISPAD 2024: Screening, Staging, and β-Cell Preservation. Horm Res Paediatr. 2024;97:529-545. PMID 39662065
  9. de Bock M, et al. ISPAD 2024: Glycemic Targets. Horm Res Paediatr. 2024;97:546-554. PMID 39701064
  10. Phillip M, et al. Consensus Guidance for Monitoring IAb-Positive Pre-Stage 3 T1D. Diabetes Care. 2024;47:1276-1298. PMID 38912694
  11. ADA Professional Practice Committee. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026. PMID 41358889
  12. Danne T, et al. Consensus on DKA Risk Management With SGLT Inhibitors. Diabetes Care. 2019;42:1147-1154. PMID 30728224
  13. Abraham MB, et al. ISPAD 2022: Assessment and management of hypoglycemia in children and adolescents. Pediatr Diabetes. 2022;23:1322-1340. PMID 36537534
  14. Beck RW, et al. CGM in adults with T1D using insulin injections. JAMA. 2017;317:371-378. PMID 28118453
  15. Brown SA, et al. Six-Month Randomized Trial of Closed-Loop Control. N Engl J Med. 2019;381:1707-1717. PMID 31618560
  16. Rickels MR. Hypoglycemia-associated autonomic failure. Ann N Y Acad Sci. 2019;1454:68-79. PMID 31389033
  17. Ziegler AG, et al. Public-health islet-autoantibody screening in Bavaria. JAMA. 2020;323:339-351. PMID 31990315
  18. Di Molfetta S, et al. Hybrid Closed Loop Network Meta-analysis. Diabetes Metab Res Rev. 2024. PMID 39298688
  19. Foster NC, et al. State of T1D Management and Outcomes from T1D Exchange. Diabetes Technol Ther. 2019;21:66-72. PMID 30657336
  20. Cengiz E, et al. ISPAD 2022: Insulin treatment in children and adolescents. Pediatr Diabetes. 2022;23:1277-1296. PMID 36537533
  21. Annan SF, et al. ISPAD 2022: Nutritional management in children and adolescents. Pediatr Diabetes. 2022;23:1297-1321. PMID 36468223
  22. Tauschmann M, et al. ISPAD 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022;23:1390-1405. PMID 36537528
  23. Tauschmann M, et al. ISPAD 2024 Diabetes Technologies: Glucose Monitoring. Horm Res Paediatr. 2024;97:615-635. PMID 39884260
  24. Deeb A, et al. ISPAD 2022: Ramadan and other religious fasting by young people with diabetes. Pediatr Diabetes. 2022;23:1512-1528. PMID 36537522
  25. ADA Professional Practice Committee. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49:S27-S49. PMID 41358893
  26. Lindholm Olinder A, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes education in children and adolescents. Pediatr Diabetes. 2022;23:1229-1242. PMID 36120721
  27. Holt RIG, et al. The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2026. PMID 42747450
  28. Holt RIG, et al. Correction: The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2026. PMID 42814152
  29. Ziegler AG, et al. International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process. Diabetologia. 2026. PMID 42720753
  30. Speight J, et al. 2026 EASD evidence-based clinical practice guideline for assessing and managing diabetes distress among adults with type 1 diabetes or type 2 diabetes. Diabetologia. 2026. PMID 42744915
  31. Olsen MT, et al. An international position statement on practical approaches for inpatient continuous glucose monitoring, insulin pumps and automated insulin delivery systems in adults. Diabetologia. 2026. PMID 42771181
  32. de Beaufort C, et al. The transition of youth with diabetes from paediatric to adult diabetes care services: a consensus report of the joint working group of ISPAD, EASD and ADA. Horm Res Paediatr. 2026. PMID 42784528
  33. NICE. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes (TA1176). Published 09 July 2026. https://www.nice.org.uk/guidance/ta1176 accessed 2026-10-22